Rodents having a humanized cluster of differentiation 47 gene

Engineering non-human animals with a humanized CD47 gene and SIRPα gene addresses the challenge of activating phagocytic clearance in cancer cells, enhancing therapeutic assessment and efficacy by promoting pro-phagocytic signals and improving engraftment of human hematopoietic stem cells.

EP4296278B1Active Publication Date: 2026-06-17REGENERON PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Patents
Current Assignee / Owner
REGENERON PHARMACEUTICALS INC
Filing Date
2015-11-25
Publication Date
2026-06-17

AI Technical Summary

Technical Problem

Current cancer therapies face challenges in activating phagocytic clearance of cancer cells and determining the molecular aspects of how cancer cells inhibit immune system responses, lacking an optimal in vivo system for assessing therapeutic potential and promoting pro-phagocytic signals.

Method used

Engineering non-human animals with a humanized CD47 gene and SIRPα gene to create rodents that express a humanized CD47 polypeptide, allowing for improved engraftment of human hematopoietic stem cells and enhanced phagocytosis of cancer cells, facilitating the development of cancer therapeutics that overcome CD47-mediated inhibition.

Benefits of technology

Provides a more efficient in vivo system for assessing cancer therapeutics by promoting phagocytic clearance and identifying drugs that enhance anti-tumor environments, overcoming systemic toxicity and improving therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF0001
    Figure IMGF0001
  • Figure IMGF0002
    Figure IMGF0002
  • Figure IMGF0003
    Figure IMGF0003
Patent Text Reader

Abstract

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
Need to check novelty before this filing date? Find Prior Art